



COMITÉ PERMANENT DES MÉDECINS EUROPÉENS  
STANDING COMMITTEE OF EUROPEAN DOCTORS



European Federation of Pharmaceutical  
Industries and Associations



## PRESS RELEASE

21 September 2011

***EU Umbrella Organizations Call for a Concrete EU-level Action for Better Adherence to Therapies***

For Immediate Release

Today, 21st of September 2011, in a lunch debate held at the European Parliament in Brussels EPF, CPME, PGEU and EFPIA brought together perspectives of patients, doctors, community pharmacists and the research-based pharmaceutical industry presenting examples of best practices on adherence to therapies and demonstrating how a coordinated, multi-stakeholder and patient-centred approach – involving patients, their carers/families, health professionals, industry, and the public, is a key factor in improving patient safety and the quality of healthcare tailored to patients' needs.

Hosting **MEPs Linda McAvan (S&D), Christofer Fjellner (PPE) and Cristian Silviu Busoi (ALDE)** opened the event by emphasising the vital *importance* of adherence to therapies *"In the EU alone 194,500 deaths each year are due to misdose of and non-adherence to prescribed medication. Poor adherence carries a huge cost, both in terms of patient safety and quality of life. It also presents a serious problem for health systems, both in terms of inferior health outcomes, unnecessary treatments and hospitalisations"* said Linda McAvan. *"The World Health Organization has stressed that increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments"* added Christofer Fjellner.

*"When long-term medication is prescribed, 50% of patients fail to adhere to the prescribed regimen"* said Prof. Przemysław Kardas from the Medical University of Lodz, Poland, who gave an overview of facts and figures on non-adherence. *"Adherence-enhancing interventions should be adopted as a routine part of normal care, and provided to every patient"*.

The patients' perspective was presented by Christos Sotirelis, who said: *"Adherence support and concordance are key components of good quality care. We believe that concordance in healthcare decision-making will lead to higher adherence by the patient. Health professionals should engage with patients as equal partners in the prescribing process, really listening to and taking account of their views. We need to empower patients and educate health professionals in order to create such an environment and promote meaningful dialogue."*

*"Doctors believe that much can be done from the communication point of view in order to improve medical adherence. eHealth tools could be used on a more regular basis in order to facilitate easy and fast communication, particularly between doctors and pharmacists, under the condition that data protection and*

*privacy is safeguarded*” added Dr Lemye, Vice-President of CPME, who presented the role of doctors in a health care team with patients and pharmacists.

Raj Patel from the National Pharmacy Association of UK, member of PGEU, illustrated how pharmacists in the UK contribute to a better medicines management through the Medicines Use Review service. *“Pharmacists’ interventions to improve adherence - such as medicine use reviews - have been shown to be effective, both in terms of patient outcomes and cost efficiency. The need for new approaches to counselling patients on medicine use will only grow as our population ages, and more of our fellow citizens take a number of different medicines at the same time. But to really make an impact we need to develop such initiatives on a large scale. Partnership with patients and other health professionals is crucial for this. The opportunities are there - we cannot afford to miss them”* said John Chave – Secretary General, PGEU.

Speaking at the conference today Mr Richard Bergström –Director General of EFPIA- explained how the pharmaceutical industry can contribute: *“EFPIA and its member companies are committed to improve adherence to therapies. This will contribute to better health outcomes and support sustainable healthcare systems in times of economic constraints. EFPIA wishes to encourage more data gathering and evaluation, encourage best-practice sharing and involve all relevant stakeholders. A medicine that is sold but not taken is a waste for everyone - only cost and no benefit”*.

Finally, in his closing speech, MEP Cristian Silviu Buşoi added: *“There is still a lack of coordination between health professionals, patients and the industry. The Steering Group of the European Innovation Partnership on Active and Healthy Ageing, which is a pilot flagship initiative within the EU “Innovation Union” has recognised the importance of addressing treatment adherence and polypharmacy. The Partnership will be an excellent opportunity to explore potential innovative solutions that can support individual patients and carers, improve data sharing and communication between health professionals, and improve the integration of care”*.

EPF, CPME, PGEU and EFPIA called for a concrete EU-level action on adherence, for example through:

- Prioritising adherence and concordance in the future EU Health Programme, in the Steering Group of the European Innovation Partnership on Active and Healthy Ageing and the Research Framework Programmes
- Setting up information and awareness campaigns targeted to patients and the public, as part of an EU strategy for health literacy and information to patients  
Using the Structural Funds to implement adherence intervention



**The Pharmaceutical Group of the European Union (PGEU)** represents more than 400,000 community pharmacists in Europe



**The European Patients' Forum (EPF)** represents 51 patient organizations and an estimated 150 million patients across the 27 Member States throughout Europe.



**The Standing Committee of European Doctors (CPME)** represents the National Medical Associations of 27 countries in Europe



**The European Federation of Pharmaceutical Industries and Associations (EFPIA)** represents the pharmaceutical industry operating in Europe.

**~About PGEU ~**

The Pharmaceutical Group of the European Union (PGEU) is the European association representing more than 400,000 community pharmacists.

PGEU's members are the national associations and professional bodies of pharmacists in 31 European countries, including EU Member States, EEA members and EU applicant countries.

For more information, please visit the PGEU website [www.pgeu.eu](http://www.pgeu.eu) or contact Ms Giovanna Giacomuzzi, PGEU Communications and Policy Officer (tel. +32 2 238 08 18) or [g.giacomuzzi@pgeu.eu](mailto:g.giacomuzzi@pgeu.eu)

**~About EPF~**

The European Patients' Forum is a not-for-profit, independent organisation and umbrella representative body for patients' organisations throughout Europe. Representing the EU patient community we advocate for patient-centred equitable healthcare, and the accessibility and quality of that healthcare in Europe. For further information visit EPF's website at [www.eu-patient.eu](http://www.eu-patient.eu) or contact Ms Kaisa Immonen-Charalambous, EPF Senior Policy Adviser [kaisa.immonen.charalambous@eu-patient.eu](mailto:kaisa.immonen.charalambous@eu-patient.eu)

**~About CPME~**

The Standing Committee of European Doctors aims to promote the highest standards of medical training and medical practice in order to achieve the highest quality of health care for all patients in Europe.

CPME represents the National Medical Associations of 27 countries in Europe and works closely with the National Medical Associations of countries that have applied for EU membership as well as specialized European medical associations.

For further information contact Mr Oscar Arias, CPME Senior Policy Adviser, (tel. 02 732 72 02) or [oscar.arias@cpme.eu](mailto:oscar.arias@cpme.eu)

**~About EFPIA~**

EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 31 national associations and 38 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 2,000 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world.

For further information contact Mr Richard Bergström, EFPIA Director General, (tel. 02 626 25 55) [newsroom@efpia.org](mailto:newsroom@efpia.org)